Transarterial Chemoembolization (TACE) is a widely applied alternative treatment for patients with hepatocellular carcinoma who are not eligible for liver resection or transplantation. However, the clinical outcomes after TACE are highly heterogeneous. There remains an urgent need for effective and efficient strategies to accurately assess tumor response and predict long-term outcomes using longitudinal and multi-center datasets. To address this challenge, we here introduce RECIST^Surv, a novel response-driven Transformer model that integrates multi-task learning with a response-driven co-attention mechanism to simultaneously perform liver and tumor segmentation, predict tumor response to TACE, and estimate overall survival based on longitudinal Computed Tomography (CT) imaging. The proposed Response-driven Co-attention layer models the interactions between pre-TACE and post-TACE features guided by the treatment response embedding. This design enables the model to capture complex relationships between imaging features, treatment response, and survival outcomes, thereby enhancing both prediction accuracy and interpretability. In a multi-center validation study, RECIST^Surv-predicted prognosis has demonstrated superior precision than state-of-the-art methods with C-indexes ranging from 0.595 to 0.780. Furthermore, when integrated with multi-modal data, RECIST^Surv has emerged as an independent prognostic factor in all three validation cohorts, with hazard ratio (HR) ranging from 1.693 to 20.7 (P = 0.001-0.042). Our results highlight the potential of RECIST^Surv as a powerful tool for personalized treatment planning and outcome prediction in hepatocellular carcinoma patients undergoing TACE. The experimental code is made publicly available at https://github.com/rushier/RECISTSurv.

During radiography, irregularities occur, leading to decrease in the diagnostic value of the images obtained. The purpose of this work was to develop a system for automated quality assurance of patient positioning in chest radiographs, with detection of suboptimal contrast, brightness, and metadata errors. The quality assurance system was trained and tested using more than 69,000 X-rays of the chest and other anatomical areas from the Unified Radiological Information Service (URIS) and several open datasets. Our dataset included studies regardless of a patient's gender and race, while the sole exclusion criterion being age below 18 years. A training dataset of radiographs labeled by expert radiologists was used to train an ensemble of modified deep convolutional neural networks architectures ResNet152V2 and VGG19 to identify various quality deficiencies. Model performance was accessed using area under the receiver operating characteristic curve (ROC-AUC), precision, recall, F1-score, and accuracy metrics. Seven neural network models were trained to classify radiographs by the following quality deficiencies: failure to capture the target anatomic region, chest rotation, suboptimal brightness, incorrect anatomical area, projection errors, and improper photometric interpretation. All metrics for each model exceed 95%, indicating high predictive value. All models were combined into a unified system for evaluating radiograph quality. The processing time per image is approximately 3 s. The system supports multiple use cases: integration into an automated radiographic workstations, external quality assurance system for radiology departments, acquisition quality audits for municipal health systems, and routing of studies to diagnostic AI models.

The skull has long been recognized and utilized in forensic investigations, evolving from basic to complex analyses with modern technologies. Advances in radiology and technology have enhanced the ability to analyze biological identifiers-sex, stature, and age at death-from the skull. The use of computed tomography imaging helps practitioners to improve the accuracy and reliability of forensic analyses. Recently, artificial intelligence has increasingly been applied in digital forensic investigations to estimate sex, stature, and age from computed tomography images. The integration of artificial intelligence represents a significant shift in multidisciplinary collaboration, offering the potential for more accurate and reliable identification, along with advancements in academia. However, it is not yet fully developed for routine forensic work, as it remains largely in the research and development phase. Additionally, the limitations of artificial intelligence systems, such as the lack of transparency in algorithms, accountability for errors, and the potential for discrimination, must still be carefully considered. Based on scientific publications from the past decade, this article aims to provide an overview of the application of computed tomography imaging in estimating sex, stature, and age from the skull and to address issues related to future directions to further improvement.

Atrial fibrillation (AF) in heart failure with reduced ejection fraction (HFrEF) has prognostic implications. Using a machine learning algorithm (FIND-AF), we aimed to explore clinical events and the cardiac magnetic resonance (CMR) characteristics of the pre-AF phenotype in HFrEF. A cohort of individuals aged ≥18 years with HFrEF without AF from the MATCH 1 and MATCH 2 studies (2018-2024) stratified by FIND-AF score. All received cardiac magnetic resonance using Cvi42 software for volumetric and T1/T2. The primary outcome was time to a composite of MACE inclusive of heart failure hospitalisation, myocardial infarction, stroke and all-cause mortality. Secondary outcomes included the association between CMR findings and FIND-AF score. Of 385 patients [mean age 61.7 (12.6) years, 39.0% women] with a median 2.5 years follow-up, the primary outcome occurred in 58 (30.2%) patients in the high FIND-AF risk group and 23 (11.9%) in the low FIND-AF risk group (hazard ratio 3.25, 95% CI 2.00-5.28, P < 0.001). Higher FIND-AF score was associated with higher indexed left ventricular mass (β = 4.7, 95% CI 0.5-8.9), indexed left atrial volume (β = 5.9, 95% CI 2.2-9.6), higher indexed left ventricular end-diastolic volume (β = 9.55, 95% CI 1.37-17.74, P = 0.022), native T1 signal (β = 18.0, 95% CI 7.0-29.1) and extracellular volume (β = 1.6, 95% CI 0.6-2.5). A pre-AF HFrEF subgroup with distinct CMR characteristics and poor prognosis may be identified, potentially guiding interventions to reduce clinical events.

The long-term association between adrenal gland volume (AGV) and type 2 diabetes (T2D) remains unclear. We aimed to determine the association between deep learning-based AGV and current glycemic status and incident T2D. In this observational study, adults who underwent abdominopelvic computed tomography (CT) for health checkups (2011-2012), but had no adrenal nodules, were included. AGV was measured from CT images using a three-dimensional nnU-Net deep learning algorithm. We assessed the association between AGV and T2D using a cross-sectional and longitudinal design. We used 500 CT scans (median age, 52.3 years; 253 men) for model development and a Multi-Atlas Labeling Beyond the Cranial Vault dataset for external testing. A clinical cohort included a total of 9708 adults (median age, 52.0 years; 5,769 men). The deep learning model demonstrated a dice coefficient of 0.71±0.11 for adrenal segmentation and a mean volume difference of 0.6± 0.9 mL in the external dataset. Participants with T2D at baseline had a larger AGV than those without (7.3 cm3 vs. 6.7 cm3 and 6.3 cm3 vs. 5.5 cm3 for men and women, respectively, all P<0.05). The optimal AGV cutoff values for predicting T2D were 7.2 cm3 in men and 5.5 cm3 in women. Over a median 7.0-year follow-up, T2D developed in 938 participants. Cumulative T2D risk was accentuated with high AGV compared with low AGV (adjusted hazard ratio, 1.27; 95% confidence interval, 1.11 to 1.46). AGV, measured using deep learning algorithms, is associated with current glycemic status and can significantly predict the development of T2D.

<i>"Just Accepted" papers have undergone full peer review and have been accepted for publication in <i>Radiology: Artificial Intelligence</i>. This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content.</i> Purpose To develop and evaluate an artificial intelligence (AI) system for generating breast ultrasound (BUS) reports. Materials and Methods This retrospective study included 104,364 cases from three hospitals (January 2020-December 2022). The AI system was trained on 82,896 cases, validated on 10,385 cases, and tested on an internal set (10,383 cases) and two external sets (300 and 400 cases). Under blind review, three senior radiologists (> 10 years of experience) evaluated AI-generated reports and those written by one midlevel radiologist (7 years of experience), as well as reports from three junior radiologists (2-3 years of experience) with and without AI assistance. The primary outcomes included the acceptance rates of Breast Imaging Reporting and Data System (BI-RADS) categories and lesion characteristics. Statistical analysis included one-sided and two-sided McNemar tests for non-inferiority and significance testing. Results In external test set 1 (300 cases), the midlevel radiologist and AI system achieved BI-RADS acceptance rates of 95.00% [285/300] versus 92.33% [277/300] (<i>P</i> < .001; non-inferiority test with a prespecified margin of 10%). In external test set 2 (400 cases), three junior radiologists had BI-RADS acceptance rates of 87.00% [348/400] versus 90.75% [363/400] (<i>P</i> = .06), 86.50% [346/400] versus 92.00% [368/400] ( <i>P</i> = .007), and 84.75% [339/400] versus 90.25% [361/400] (<i>P</i> = .02) with and without AI assistance, respectively. Conclusion The AI system performed comparably to a midlevel radiologist and aided junior radiologists in BI-RADS classification. ©RSNA, 2025.

Lung cancer remains the leading cause of cancer-related mortality worldwide, due to lacking effective early-stage screening approaches. Imaging, such as low-dose CT, poses radiation risk, and biopsies can induce some complications. Additionally, traditional serum tumor markers lack diagnostic specificity. This highlights the urgent need for precise and non-invasive early detection techniques. This systematic review aims to evaluate the limitations of conventional screening methods (imaging/biopsy/tumor markers), seek breakthroughs in liquid biopsy for early lung cancer detection, and assess the potential value of Artificial Intelligence (AI), thereby providing evidence-based insights for establishing an optimal screening framework. We systematically searched the PubMed database for the literature published up to May 2025. Key words include "Artificial Intelligence", "Early Lung cancer screening", "Imaging examination", "Innovative technologies", "Liquid biopsy", and "Puncture biopsy". Our inclusion criteria focused on studies about traditional and innovative screening methods, with an emphasis on original research concerning diagnostic performance or high-quality reviews. This approach helps identify critical studies in early lung cancer screening. Novel liquid biopsy techniques are non-invasive and have superior diagnostic efficacy. AI-assisted diagnostics further enhance accuracy. We propose three development directions: establishing risk-based liquid biopsy screening protocols, developing a stepwise "imaging-AI-liquid biopsy" diagnostic workflow, and creating standardized biomarker panel testing solutions. Integrating traditional methodologies, novel liquid biopsies, and AI to establish a comprehensive early lung cancer screening model is important. These innovative strategies aim to significantly increase early detection rates, substantially enhancing lung cancer control. This review provides both theoretical guidance for clinical practice and future research.

Brain tumor classification using Magnetic Resonance Imaging (MRI) images is an important and emerging field of medical imaging and artificial intelligence in the current world. With advancements in technology, particularly in deep learning and machine learning, researchers and clinicians are leveraging these tools to create complex models that, using MRI data, can reliably detect and classify tumors in the brain. However, it has a number of drawbacks, including the intricacy of tumor types and grades, intensity variations in MRI data and tumors varying in severity. This paper proposes a Multi-Grade Hierarchical Classification Network Model (MGHCN) for the hierarchical classification of tumor grades in MRI images. The model's distinctive feature lies in its ability to categorize tumors into multiple grades, thereby capturing the hierarchical nature of tumor severity. To address variations in intensity levels across different MRI samples, an Improved Adaptive Intensity Normalization (IAIN) pre-processing step is employed. This step standardizes intensity values, effectively mitigating the impact of intensity variations and ensuring more consistent analyses. The model renders utilization of the Dual Tree Complex Wavelet Transform with Enhanced Trigonometric Features (DTCWT-ETF) for efficient feature extraction. DTCWT-ETF captures both spatial and frequency characteristics, allowing the model to distinguish between different tumor types more effectively. In the classification stage, the framework introduces the Adaptive Hierarchical Optimized Horse Herd BiLSTM Fusion Network (AHOHH-BiLSTM). This multi-grade classification model is designed with a comprehensive architecture, including distinct layers that enhance the learning process and adaptively refine parameters. The purpose of this study is to improve the precision of distinguishing different grades of tumors in MRI images. To evaluate the proposed MGHCN framework, a set of evaluation metrics is incorporated which includes precision, recall, and the F1-score. The structure employs BraTS Challenge 2021, Br35H, and BraTS Challenge 2023 datasets, a significant combination that ensures comprehensive training and evaluation. The MGHCN framework aims to enhance brain tumor classification in MRI images by utilizing these datasets along with a comprehensive set of evaluation metrics, providing a more thorough and sophisticated understanding of its capabilities and performance.

To assess the methodological quality of radiomics-based studies on bone chondrosarcoma using METhodological RadiomICs Score (METRICS) and Radiomics Quality Score (RQS). A literature search was conducted on EMBASE and PubMed databases for research papers published up to July 2024 and focused on radiomics in bone chondrosarcoma, with no restrictions regarding the study aim. Three readers independently evaluated the study quality using METRICS and RQS. Baseline study characteristics were extracted. Inter-reader reliability was calculated using intraclass correlation coefficient (ICC). Out of 68 identified papers, 18 were finally included in the analysis. Radiomics research was aimed at lesion classification (n = 15), outcome prediction (n = 2) or both (n = 1). Study design was retrospective in all papers. Most studies employed MRI (n = 12), CT (n = 3) or both (n = 1). METRICS and RQS adherence rates ranged between 37.3-94.8% and 2.8-44.4%, respectively. Excellent inter-reader reliability was found for both METRICS (ICC = 0.961) and RQS (ICC = 0.975). Among the limitations of the evaluated studies, the absence of prospective studies and deep learning-based analyses was highlighted, along with the limited adherence to radiomics guidelines, use of external testing datasets and open science data. METRICS and RQS are reproducible quality assessment tools, with the former showing higher adherence rates in studies on chondrosarcoma. METRICS is better suited for assessing papers with retrospective design, which is often chosen in musculoskeletal oncology due to the low prevalence of bone sarcomas. Employing quality scoring systems should be promoted in radiomics-based studies to improve methodological quality and facilitate clinical translation. Employing reproducible quality scoring systems, especially METRICS (which shows higher adherence rates than RQS and is better suited for assessing retrospective investigations), is highly recommended to design radiomics-based studies on chondrosarcoma, improve methodological quality and facilitate clinical translation. The low scientific and reporting quality of radiomics studies on chondrosarcoma is the main reason preventing clinical translation. Quality appraisal using METRICS and RQS showed 37.3-94.8% and 2.8-44.4% adherence rates, respectively. Room for improvement was noted in study design, deep learning methods, external testing and open science. Employing reproducible quality scoring systems is recommended to design radiomics studies on bone chondrosarcoma and facilitate clinical translation.

Deep learning (DL) models have shown promise in predicting axillary lymph node (ALN) status. However, most existing DL models were classification-only models and did not consider the practical application scenarios of multi-view joint prediction. Here, we propose a Multi-Task Learning (MTL) and Multi-Instance Learning (MIL) framework that simulates the real-world clinical diagnostic scenario for ALN status prediction in breast cancer. Ultrasound images of the primary tumor and ALN (if available) regions were collected, each annotated with a segmentation label. The model was trained on a training cohort and tested on both internal and external test cohorts. The proposed two-stage DL framework using one of the Transformer models, Segformer, as the network backbone, exhibits the top-performing model. It achieved an AUC of 0.832, a sensitivity of 0.815, and a specificity of 0.854 in the internal test cohort. In the external cohort, this model attained an AUC of 0.918, a sensitivity of 0.851 and a specificity of 0.957. The Class Activation Mapping method demonstrated that the DL model correctly identified the characteristic areas of metastasis within the primary tumor and ALN regions. This framework may serve as an effective second reader to assist clinicians in ALN status assessment.